How Clinical Trials Work for Research and Drug Development

Last updated 6 days ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.

Clinical trials power medical progress. They are carefully regulated research studies involving human volunteers that determine whether new ways to prevent, detect, or treat diseases are safe and effective.

From the most common over-the-counter pain reliever to the most advanced cancer therapies, every medical product available today is the result of a long and rigorous clinical trial process. This system, overseen by the U.S. government, serves as the critical bridge between a promising idea in a laboratory and a proven treatment available to patients.

What Are Clinical Trials and Why Are They Essential

Clinical trials are the foundation upon which all modern, evidence-based medicine is built. They provide the high-quality data that allows doctors, patients, and regulatory agencies to make informed decisions about health care. Without them, medicine would be based on theory and anecdote rather than scientific proof.

Defining the Clinical Trial

A clinical trial is not a haphazard experiment but a meticulously planned study that follows a strict set of rules and ethical guidelines. Each trial is guided by a formal plan called a protocol, which details every aspect of the study, including its goals, eligibility requirements for participants, the procedures and tests that will be performed, and the length of the study.

The National Institutes of Health (NIH), the U.S. government’s primary medical research agency, has a precise definition for what constitutes a clinical trial: “a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.”

This definition contains four essential questions that determine if a study is a clinical trial:

• Does the study involve human participants?
• Are the participants prospectively assigned to an intervention?
• Is the study designed to evaluate the effect of the intervention on the participants?
• Is the effect being evaluated a health-related biomedical or behavioral outcome?

The phrase “prospectively assigned” is the scientific heart of this definition. It signifies an active, controlled process where researchers deliberately introduce a variable—the intervention—to measure its effect.

This active assignment is what separates a clinical trial from an observational study, where researchers simply observe outcomes without intervening. By assigning participants to different groups, researchers can control for other factors and establish a cause-and-effect relationship, providing the strongest possible evidence that an intervention truly works.

Foundation of Modern Medicine

Every medical treatment, cure, and prevention strategy in use today exists because of clinical trials. They are the primary and most reliable method for moving a promising concept from the laboratory into clinical practice.

This process is legally required by the U.S. Food and Drug Administration (FDA) before any new drug, medical device, or biologic (such as a vaccine) can be made available to the public.

It is a common misconception that a “new” treatment is automatically a “better” one. The reality is that the true benefits and risks of a potential medical treatment are unknown until comprehensive clinical research is completed. Trials provide the evidence-based information that doctors rely on to recommend treatments and that patients need to make informed decisions about their care.

Beyond New Drugs: Types of Clinical Trials

While often associated with testing new pharmaceuticals, the scope of clinical trials is far broader, addressing a wide spectrum of health-related questions. The existence of these varied trial types shows that the U.S. public health apparatus defines “health” as more than just the absence of disease; it encompasses overall well-being, lifestyle, and early detection.

Major types of trials include:

Treatment Trials: These are the most common type, testing new treatments, new combinations of drugs, or new approaches to surgery or radiation therapy.

Prevention Trials: These studies look for better ways to prevent a disease from occurring in the first place or to prevent it from returning in people who have already been treated.

Diagnostic and Screening Trials: Diagnostic trials study or compare tests and procedures for diagnosing a condition, while screening trials aim to find the best way to detect diseases early, sometimes even before symptoms appear.

Behavioral Trials: These trials evaluate or compare ways to promote behavioral changes designed to improve health, such as new methods for quitting smoking or adopting a healthier diet.

Quality of Life Trials: Also known as supportive care trials, these explore ways to improve comfort and quality of life for individuals living with a chronic illness.

The Journey of a New Medicine: Five-Step Regulatory Process

Before a new medicine can reach the pharmacy, it must pass through a long and arduous development and review process defined by the FDA. This multi-step journey is designed to build a comprehensive case for a drug’s safety and effectiveness.

The overall probability of a new drug successfully navigating this entire process is only about 12%, a figure that underscores the system’s immense rigor. This low success rate is not a flaw but a feature of a system designed with an exceptionally high bar for public protection.

Each step acts as a filter, ensuring that only the most promising and safest compounds advance.

Discovery and Preclinical Research

The journey begins in the laboratory, long before any human is involved. Scientists first identify a “drug target”—a specific molecule in the body, such as a protein or a gene, that is involved in a disease. They then screen thousands of compounds to find a “lead compound” that shows promise in affecting this target.

Once promising compounds are identified, they enter preclinical research. This stage involves extensive laboratory tests (in vitro, or in a test tube) and animal studies (in vivo). The primary goal of this phase is to assess basic safety and determine if a compound has the potential to cause serious harm or toxicity.

This is a critical safety check that must be completed before a drug can ever be considered for human testing.

The Investigational New Drug Application

If preclinical research shows that a drug has a promising effect and an acceptable safety profile, the sponsor (typically a pharmaceutical company) compiles all of this data into an Investigational New Drug (IND) application and submits it to the FDA.

This comprehensive application must be reviewed and approved by the FDA before the sponsor is legally permitted to begin testing the drug in human volunteers.

Clinical Research in Humans

This is the stage where the drug is tested in people through the carefully structured phases of clinical trials. The goal is to gather definitive data on whether the drug is safe and effective for its intended use. This step is the longest and most complex part of the entire development process.

FDA Review Process

After a drug has successfully completed the first three phases of clinical trials, the sponsor submits a New Drug Application (NDA) or a Biologics License Application (BLA) to the FDA. This application is an enormous collection of all the data gathered from the discovery, preclinical, and clinical research stages.

A multidisciplinary team of FDA experts—including doctors, chemists, statisticians, microbiologists, and pharmacologists—then conducts an exhaustive review of this data. They independently analyze the sponsor’s findings, weigh the drug’s demonstrated benefits against its potential risks, and decide whether to grant approval for the drug to be marketed and sold in the United States.

This separation of duties—where the sponsor conducts the research and the FDA independently reviews it—is a cornerstone of the U.S. regulatory model. It creates a crucial check and balance, preventing the entity with a financial stake in the drug’s success from also being the final arbiter of its safety.

FDA Post-Market Safety Monitoring

The FDA’s oversight does not end once a drug is approved. The agency continues to monitor the drug’s safety as it is used by the general population in a process known as post-market surveillance.

This ongoing monitoring, often structured as a Phase IV clinical trial, is designed to detect any rare or long-term side effects that may not have become apparent during the more controlled and limited studies conducted before approval.

The Phases of Clinical Trials

The human testing portion of drug development is not a single event but a series of distinct stages, or “phases.” Each phase is a separate clinical trial designed to answer a different set of scientific questions.

The number of participants and the complexity of the study grow with each successive phase, creating a progressive de-risking strategy. This structure is both economically and ethically sound. By starting with small, safety-focused studies, sponsors can answer the most fundamental questions first, limiting both financial investment and human risk on compounds that are unlikely to succeed.

Phase 0: Exploratory Studies

Phase 0 trials are optional, exploratory studies designed to accelerate the drug development process. The goal is to get a very early look at how a drug behaves in the human body before committing to larger, more expensive trials.

Goal: To gather preliminary data on a drug’s pharmacokinetics (what the body does to the drug) and pharmacodynamics (what the drug does to the body).

Process: A very small number of volunteers, typically 10 to 15, receive a single, subtherapeutic dose—a dose so small that it is not expected to have any treatment effect. Researchers then use highly sensitive tools to see if the drug reaches its intended target and how it is processed by the body.

Key Feature: Because the dose is so low, there is almost no chance of medical benefit for the participant, but there is also very little risk. This allows researchers to make “fast-fail” decisions, quickly weeding out unpromising drug candidates.

Phase I: Is It Safe?

This is the first time a new investigational treatment is tested in a group of people to determine its safety profile.

Goal: To evaluate the treatment’s safety, identify a safe dosage range, and document side effects.

Participants: A small group, typically 20 to 100 people. These are often healthy volunteers, but for some diseases like cancer, Phase I trials may enroll patients with the condition.

Duration: Usually lasts for several months.

Phase II: Does It Work?

Once a treatment has been found to be reasonably safe in Phase I, it moves to a larger group of people who have the specific disease or condition it is intended to treat.

Goal: To determine if the treatment is effective (has efficacy) and to continue evaluating its safety and side effects in the target patient population.

Participants: A larger group, typically ranging from 100 to 300 people with the condition.

Duration: Can last from several months to two years.

Phase III: Is It Better?

This is the most advanced and large-scale phase of pre-approval testing. The data gathered in Phase III trials typically forms the primary basis for the FDA’s decision on whether to approve a new treatment.

Goal: To confirm the treatment’s effectiveness, monitor its side effects, and compare it to commonly used standard treatments or a placebo. The aim is to collect comprehensive information that will allow the new treatment to be used safely in a broad population.

Participants: A large group of several hundred to 3,000 volunteers who have the disease or condition.

Duration: Typically lasts from one to four years.

Phase IV: What Else Do We Need to Know?

Also known as Post-Market Surveillance studies, these trials occur after the FDA has approved a treatment and it is available to the public.

Goal: To track the treatment’s safety in the general population over the long term. This phase is crucial for gathering additional information about the treatment’s benefits, risks, and optimal use, and for identifying any rare or long-term side effects that were not detected in the smaller, more controlled Phase III trials.

Participants: Several thousand people with the disease or condition who are receiving the treatment as part of their standard medical care.

Duration: These studies are ongoing and have no set duration.

The distinction between the highly controlled environment of Phases I-III and the “real world” of Phase IV is critical. Pre-approval trials use strict eligibility criteria, often excluding patients with multiple health conditions or those taking other medications. Phase IV is where a drug’s performance is truly tested in the diverse general population.

Clinical Trial Phases Summary Table

How Researchers Ensure Reliable Results

To produce trustworthy results, clinical trials must be designed to minimize bias. Bias can come from many sources—a patient’s hope for a cure, a doctor’s belief in a new therapy, or simple chance.

To combat this, researchers employ a set of powerful scientific methods. When used together, these methods create what is known as a randomized, double-blind, placebo-controlled (RDBPC) trial, which is widely considered the “gold standard” for providing the strongest possible evidence of a treatment’s true effect.

This “gold standard” design reflects a deep, institutionalized skepticism about human perception. It acknowledges that the hopes of patients and the expectations of doctors can create the illusion of a treatment effect where none exists.

These methods work together as a sophisticated system to achieve one primary goal: to isolate the effect of the intervention. By systematically eliminating other possible explanations for the results, researchers can confidently attribute any observed difference to the one thing that is different between the study groups—the experimental treatment.

Randomization: Assigning Participants by Chance

In a randomized trial, participants are assigned to different treatment groups using a method based on chance, similar to flipping a coin. This is not done by the choice of the doctor or the patient.

Purpose: Randomization is the most effective way to prevent selection bias and ensure that the groups being compared are as similar as possible at the start of the study. It balances the distribution of known factors (like age and disease severity) and unknown factors that could influence the outcome.

This way, if one group does better than the other, researchers can be confident that the difference is due to the treatment and not some pre-existing disparity between the groups.

Blinding: Who Knows What?

Blinding is the practice of keeping the participants and/or the investigators unaware of which treatment is being administered.

Purpose: Knowing which treatment is being given can influence behavior and assessments. A patient who knows they are receiving a new drug may report feeling better simply due to optimism (the placebo effect). A doctor who knows a patient is on the new drug might unconsciously pay closer attention to them or interpret their symptoms more favorably.

Blinding prevents these conscious and unconscious biases from distorting the study’s results.

Types of Blinding:

Single-Blind: The participants do not know which treatment they are receiving, but the research team does.

Double-Blind: Neither the participants nor the research team (doctors, nurses, outcome assessors) knows who is receiving the experimental treatment versus the control. This is the most rigorous and preferred method for eliminating bias. The treatment assignments are coded, and the code is only broken at the end of the study, or in an emergency if a patient’s safety requires it.

Controls and Placebos

A controlled trial is one that includes a comparison, or “control,” group that does not receive the experimental treatment.

Purpose: The control group provides a baseline against which to measure the effects of the new treatment. Without a control group, it would be impossible to know if a patient’s improvement was due to the drug, the placebo effect, or simply the natural course of their disease.

Types of Controls:

Standard of Care: The best currently available treatment for the condition. The trial is then designed to see if the new treatment is better than the existing one.

Placebo: A substance or procedure that has no active therapeutic ingredients and is designed to look, taste, or feel identical to the active treatment being tested.

Ethical Use of Placebos: Placebos are a powerful scientific tool, but their use is strictly regulated. It is considered unethical to use a placebo if an effective standard treatment already exists for a serious condition. In such cases, the new drug would be tested against the standard treatment.

Placebos are generally only used when there is no established treatment available, and participants are always informed of the possibility of receiving a placebo before they agree to enroll in a trial.

The Participant Experience

Clinical trials are entirely dependent on the willingness of volunteers to participate. Understanding the experience from their perspective—their motivations, the balance of risks and benefits they face, and their practical needs—is crucial for the success of the entire medical research enterprise.

Why People Volunteer

People choose to participate in clinical trials for a combination of personal and altruistic reasons.

Altruism: For many, the primary motivation is the desire to contribute to scientific knowledge and to help others who may face the same disease in the future. A survey of trial participants found that the “ability to contribute to science” was the most frequently cited reason for joining.

Personal Health: Participants with existing health conditions often join to gain access to innovative treatments years before they might become widely available. They also receive very close medical attention and monitoring from the expert staff of the research team. Many report feeling more educated and empowered in their own health care as a result of their participation.

Healthy Volunteers: Many trials, especially in early phases, require healthy volunteers. These individuals participate to help researchers establish a baseline for safety and to understand how a drug behaves in a body unaffected by disease, providing essential comparison data.

Potential Benefits and Risks

The decision to join a clinical trial is a significant one that requires a careful consideration of the potential benefits and risks. Federal regulations mandate that all of these be clearly explained to a potential participant before they decide to enroll.

Potential Benefits:

• Access to new and innovative treatments before they are widely available
• Receiving expert medical care at leading healthcare facilities, with close monitoring of health and any side effects
• Playing a more active and informed role in one’s own health care
• The opportunity to make a valuable contribution to medical research that can help others

Potential Risks:

• The new treatment may have unexpected or serious side effects. While most trials involve only minor discomfort, some can result in complications that require medical attention
• The experimental treatment may not be effective for the participant, or it may be less effective than the standard treatment
• Participation can be inconvenient and time-consuming, potentially requiring more frequent visits to the study site, more tests, hospital stays, or complex medication schedules
• There may be financial costs associated with participation, such as for travel, lodging, or childcare, that are not covered by the study or insurance

This balance highlights an inherent tension between the roles of “patient” and “research subject.” A patient’s primary goal is to receive the best possible care to get well. A research subject’s primary role is to contribute to scientific knowledge, which may or may not directly benefit them personally.

The entire ethical oversight system is designed to navigate this tension and ensure that the well-being of the patient is never sacrificed for the needs of the research.

The Rise of Patient-Centricity

There is a growing movement within the research community to design and conduct clinical trials in a more “patient-centric” way, treating participants as valued partners in the research process rather than just as sources of data.

This shift is not merely an ethical consideration; it is a pragmatic response to a critical scientific and business problem. Globally, up to 85% of clinical trials fail to meet their recruitment goals, creating a massive bottleneck in the development of new medicines.

A patient-centric approach addresses the root causes of this problem by listening to patients and caregivers to understand how a trial will impact their daily lives—their work, family, and financial stability. This can lead to more practical trial designs that:

• Reduce the burden of participation by offering transportation to trial sites or using digital tools for remote monitoring
• Provide fair compensation for the participant’s time and effort
• Improve communication and transparency, making participants feel valued

When trials are designed around the needs of participants, recruitment and retention rates improve, the quality of the data collected is higher, and the research is ultimately more successful and relevant.

Ethical and Safety Oversight System

In response to historical episodes of unethical research, the United States has established a robust, multi-layered system of regulations and independent oversight bodies to protect the rights, safety, and well-being of every clinical trial participant.

This system is required by federal law and is a direct consequence of past failures, designed to ensure such abuses are not repeated. Each component of this system is a bulwark against a specific potential harm: informed consent protects against deception, independent review protects against institutional pressure, and ongoing monitoring protects against unforeseen risks.

These three pillars of protection—Informed Consent, Institutional Review Boards, and Data and Safety Monitoring Boards—form an interlocking system that operates at different levels and at different times to provide a layered defense for participants.

• Informed Consent operates at the individual level and is continuous, empowering the participant throughout the trial
• The Institutional Review Board (IRB) operates at the institutional level and acts before the trial begins, ensuring its ethical design
• The Data and Safety Monitoring Board (DSMB) operates at the data level and acts during the trial, protecting the entire group of participants from emerging harm

Informed Consent: Your Right to Know and Choose

Informed consent is the cornerstone of ethical research. It is not just a form to be signed but an ongoing process of communication between the research team and the potential participant. The process must ensure that individuals have all the information they need to make a voluntary and informed decision about whether to participate.

Federal law requires that every potential participant be given an informed consent document written in clear, easy-to-understand language. This document must include detailed information about:

• The purpose of the study, how long it will last, and what procedures will be involved
• All reasonably foreseeable risks, discomforts, and potential benefits
• Any available alternative treatments
• The extent to which the participant’s personal information will be kept confidential
• A clear statement that participation is completely voluntary and that the participant can withdraw from the study at any time without penalty and without affecting their regular medical care

Institutional Review Boards: Independent Ethics Committees

Before any clinical trial involving human subjects can begin, it must be reviewed and approved by an Institutional Review Board (IRB).

Who They Are: An IRB is an independent committee made up of a diverse group of at least five members, including scientists, non-scientists, and at least one member who is not affiliated with the research institution. This diversity ensures that the research is reviewed from multiple ethical, scientific, and community perspectives.

What They Do: The IRB’s primary mission is to protect the rights and welfare of research participants. They meticulously review the study protocol, the informed consent process, and the plans for monitoring participant safety to ensure that risks are minimized and are reasonable in relation to the potential benefits of the research.

The IRB has the authority to approve a study, require modifications to it, or disapprove it entirely. They also conduct ongoing reviews of the research at least once a year for the duration of the study.

Data and Safety Monitoring Boards: Watchful Eye on Ongoing Trials

For many clinical trials, especially those that are large, multi-site, or involve high-risk interventions, an additional layer of oversight is provided by a Data and Safety Monitoring Board (DSMB).

Who They Are: A DSMB is a group of independent experts, including physicians and biostatisticians, who have no financial or other conflicts of interest with the trial they are overseeing.

What They Do: The DSMB’s role is to periodically review the data from a clinical trial as it is being collected. They look for emerging safety concerns or evidence that one treatment is clearly more effective than another.

Based on their review, a DSMB has the power to recommend that a trial be modified or even stopped early—either because of unexpected harm, overwhelming benefit, or because it has become clear the trial will not be able to answer its research question.

Key Players: Who Funds, Runs, and Regulates Clinical Trials

The clinical trial ecosystem is a complex partnership involving private industry, government agencies, and academic institutions. Each player has a distinct and vital role in bringing new medical innovations to the public safely and effectively.

This system relies on a symbiotic relationship: industry provides the innovation and investment, while the government provides the regulatory framework and public funding for research that may not be commercially profitable. This interdependence also creates a healthy tension, with the FDA acting as the crucial firewall between commercial interests and public safety.

Sponsors: The Driving Force

The sponsor is the individual, company, institution, or organization that takes responsibility for initiating, managing, and/or financing a clinical trial. Sponsors can come from various sectors:

Pharmaceutical and Biotechnology Companies: Companies like Pfizer, AstraZeneca, and Amgen are the primary sponsors of trials for the new drugs and therapies they develop.

Federal Agencies: The U.S. government, primarily through the National Institutes of Health (NIH), is a major sponsor and funder of clinical research.

Academic Medical Centers: Universities and their affiliated hospitals often sponsor and conduct trials led by their own physician-scientists.

Foundations and Voluntary Groups: Non-profit organizations focused on specific diseases may also sponsor research.

Many sponsors also hire Contract Research Organizations (CROs), which are companies that specialize in managing the complex operational aspects of a clinical trial, from site coordination to data management.

National Institutes of Health: Major Funder and Research Driver

The NIH, an agency of the U.S. Department of Health and Human Services, is the largest public funder of biomedical research in the world. It plays a pivotal role in the U.S. clinical trial landscape by:

Funding Research: The NIH provides billions of dollars in grants to researchers at universities, medical schools, and other research institutions across the country and around the world to conduct clinical trials.

Conducting Research: The NIH conducts its own research studies, known as intramural research, at its facilities, most notably the NIH Clinical Center in Bethesda, Maryland—the largest hospital in the world devoted entirely to clinical research.

Ensuring Transparency: The NIH has established a powerful policy for transparency and accountability. It requires that all clinical trials funded by the agency must be registered in a public database, ClinicalTrials.gov, and must publicly report their summary results. This prevents “publication bias”—where only studies with positive results are published—and ensures that the public’s investment in research yields public knowledge, regardless of the outcome.

FDA: The Nation’s Gatekeeper

The FDA is the federal agency responsible for protecting public health by ensuring that human drugs, biologics, and medical devices are safe and effective. The FDA’s role is one of regulation and oversight, not execution.

It is a common misconception that the FDA conducts its own trials; it does not. The FDA oversees clinical trials for safety and reviews the resulting data, but it does NOT conduct the trials themselves.

Its key responsibilities in the clinical trial process include:

• Reviewing the results of preclinical studies and approving the IND application before any human testing can begin
• Monitoring the conduct of clinical trials to ensure they comply with federal regulations and that participants are protected from unreasonable risks
• Thoroughly reviewing all the data from a completed trial series to make the final decision on whether to approve a new product for the U.S. market
• Monitoring the safety of products after they have been approved and are in public use

The Pursuit of Diversity in Clinical Trials

For a clinical trial’s results to be meaningful for the entire population, the group of participants in that trial must reflect the diversity of the people who will ultimately use the treatment.

Achieving diversity in clinical trials is a matter of scientific accuracy, safety, and fundamental health equity.

Why Representation Matters

Scientific Validity: A person’s race, ethnicity, age, and sex can all influence how they respond to a medicine. For example, genetic variations more common in certain ancestral populations can affect how a drug is metabolized, potentially altering its effectiveness or increasing the risk of side effects.

If a trial’s participants are not diverse, its findings may not be generalizable, meaning the treatment could be less effective or even unsafe for underrepresented groups.

Health Equity: Historically, clinical trial participants have been predominantly white. When new treatments are developed based on data from such a homogenous group, it can perpetuate and worsen existing health disparities. Ensuring that trials are inclusive helps develop treatments that are safe and effective for everyone, leading to more equitable health outcomes.

Advancing Discovery: The future of medicine lies in “personalized medicine,” with treatments tailored to an individual’s genetic makeup. However, the genomic databases that fuel this innovation are overwhelmingly built on data from people of European descent.

If this lack of diversity is not corrected, the promise of personalized medicine could become a reality for only a portion of the population, creating a new and profound form of health inequity. Diversifying trials today is therefore an urgent prerequisite for an equitable future of medicine.

Barriers to Participation

Despite its importance, diversity in clinical trials remains a significant challenge. Minority populations are consistently underrepresented. For example, Black Americans account for roughly 13% of the U.S. population but make up only 5% of trial participants, while Hispanic and Latino individuals account for 19% of the population but only 1% of participants.

This disparity stems from a complex mix of historical, social, and economic barriers:

Mistrust: A deep and historically justified mistrust in the medical establishment, stemming from past abuses like the Tuskegee Syphilis Study and experiences of discrimination, is a major barrier for many minority communities.

Logistical and Socioeconomic Factors: Underrepresented populations are more likely to face practical obstacles, such as a lack of reliable transportation to trial sites, an inability to take time off from work, childcare needs, or inadequate health insurance.

Lack of Awareness and Access: Trial sites are often located in academic medical centers that may not be easily accessible to diverse communities. Furthermore, information about trials may not be provided in a culturally or linguistically appropriate manner.

This lack of diversity can create a vicious cycle that perpetuates health inequity. When trials are not representative, the resulting treatments may be less effective for underrepresented groups. This negative real-world experience can then reinforce the initial mistrust of the medical system, making recruitment for future trials even more difficult and deepening health disparities.

Building a More Inclusive Future

Recognizing this critical issue, the FDA, NIH, pharmaceutical companies, and research institutions are implementing strategies to improve diversity in clinical trials. These efforts represent a multifaceted approach to rebuilding trust and removing barriers:

Community Engagement: Building long-term, trusting relationships with community leaders, patient advocacy groups, and local organizations. This involves listening to the community’s concerns and engaging them in the trial design process.

Improving Access: Establishing trial sites in underserved communities, such as at community health centers, and using decentralized trial methods and digital tools to reduce the need for travel.

Cultural Competency: Developing trial materials in multiple languages and ensuring they are culturally sensitive. A key strategy is also to increase the diversity of the clinical research workforce itself, so that investigators and staff reflect the communities they serve.

Transparency and Education: Committing to clear communication about the trial process and sharing the results with participating communities to demonstrate the value of their contribution.

How to Find and Participate in Clinical Trials

For individuals considering a clinical trial for themselves or a loved one, navigating the system can seem daunting. However, numerous resources are available to help. The system’s complexity means that patients and their families often need to be proactive—asking questions, doing research, and advocating for themselves.

How to Find a Clinical Trial

There is no single, universal list of every clinical trial, so it is often helpful to consult multiple sources.

Start with Your Doctor: The best place to begin is by talking with your doctor or another member of your health care team. They understand your medical situation and can help you search for appropriate trials.

Use Online Search Tools:

ClinicalTrials.gov: This is the largest and most comprehensive database of clinical trials. Maintained by the NIH’s National Library of Medicine, it lists publicly and privately funded studies for a vast range of diseases and conditions conducted around the world.

National Cancer Institute Search Tool: For those seeking cancer-related trials, the NCI provides a user-friendly search tool for NCI-funded trials. They also offer assistance from trained information specialists via phone at 1-800-4-CANCER (1-800-422-6237).

Other Resources: Many major medical centers, universities, pharmaceutical companies, and patient advocacy groups maintain lists of the trials they are conducting or supporting on their websites.

Understanding the Costs of Participation

A common concern for potential participants is the cost of being in a clinical trial. The costs are typically divided into two categories, with a payment structure that reflects the ethical line between treatment and research.

Research Costs: These are costs associated with the purely experimental aspects of the study, such as the investigational drug itself, extra lab tests, or imaging done solely for research purposes. These costs are generally covered by the trial’s sponsor and are not billed to the participant or their insurance.

Patient Care Costs: These are the routine costs of medical care that a participant would have even if they were not in a trial. This includes doctor visits, hospital stays, and standard medical tests. These costs are typically billed to the participant’s health insurance plan.

Federal law, including the Affordable Care Act, requires most health insurance plans, as well as Medicare and Medicaid, to cover these routine patient care costs in approved clinical trials.

Out-of-Pocket Costs: Participants may still be responsible for their insurance plan’s regular co-pays and deductibles. They may also face non-medical costs, such as travel to the trial site, lodging, and meals.

It is essential to ask the study coordinator upfront if the trial sponsor or any non-profit organizations provide financial assistance or reimbursement for these expenses.

Clinical trials represent one of humanity’s most systematic approaches to improving health and treating disease. The process, while complex and time-consuming, reflects society’s commitment to ensuring that new medical treatments are both safe and effective before they reach the general public.

The system of checks and balances—from rigorous scientific design to independent ethical oversight—exists to protect participants while advancing medical knowledge. As medicine moves toward more personalized treatments and novel therapies, the need for diverse, well-designed clinical trials becomes even more critical.

For patients, understanding how clinical trials work empowers them to make informed decisions about their care and potentially access cutting-edge treatments. For society, supporting this research infrastructure ensures continued medical progress that benefits everyone.

The future of medicine depends on the willingness of volunteers to participate in this carefully regulated process of discovery. Each trial represents not just a test of a new treatment, but a step forward in the ongoing effort to understand and conquer disease.

Our articles make government information more accessible. Please consult a qualified professional for financial, legal, or health advice specific to your circumstances.